Publication: Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
Loading...
Identifiers
Date
2019-11-14
Authors
Fraile-Ribot, Pablo A.
Zamorano, Laura
Orellana, Rocio
Del Barrio-Tofiño, Ester
Sanchez-Diener, Irina
Cortes-Lara, Sara
Lopez-Causape, Carla
Cabot, Gabriel
Bou, German
Martinez-Martinez, Luis
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
ASM Journals
Metrics
Export
Abstract
Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC.
Description
MeSH Terms
Anti-Bacterial agents
Azabicyclo compounds
Colistin
Humans
Imipenem
Mutation
Pseudomonas infections
Pseudomonas aeruginosa
beta-Lactam Resistance
beta-Lactamases
Azabicyclo compounds
Colistin
Humans
Imipenem
Mutation
Pseudomonas infections
Pseudomonas aeruginosa
beta-Lactam Resistance
beta-Lactamases
DeCS Terms
Antibacterianos
Colistina
Compuestos de azabiciclo
Humanos
Infecciones por pseudomonas
Mutacion
Pseudomonas aeruginosa
Resistencia betalactamica
beta-Lactamasas
Colistina
Compuestos de azabiciclo
Humanos
Infecciones por pseudomonas
Mutacion
Pseudomonas aeruginosa
Resistencia betalactamica
beta-Lactamasas
CIE Terms
Keywords
Pseudomonas aeruginosa, Antibiotic resistance, Extensively drug resistant, Imipenem-relebactam, Multidrug resistance, Whole-genome sequencing, β-lactam resistance mechanisms
Citation
Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, et al. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e02165-19